This company is a Genetic Tests To Support Family Planning Stages of Life.
Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate and comprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 6, 2021 | Series D | ¥250M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Zhongjin Qide | — | Series D |
General Technology Venture Capital | — | Series D |